

## **Product** Data Sheet

## SD-1008

 Cat. No.:
 HY-107595

 CAS No.:
 960201-81-4

 Molecular Formula:
 C<sub>18</sub>H<sub>19</sub>NO<sub>5</sub>


 Molecular Weight:
 329.35

Target: JAK; STAT; Apoptosis

Pathway: Epigenetics; JAK/STAT Signaling; Stem Cell/Wnt; Apoptosis

Storage: Please store the product under the recommended conditions in the Certificate of

Analysis.



**BIOLOGICAL ACTIVITY** 

Description	SD-1008 is a potent JAK inhibitor. SD-1008 inhibits tyrosyl phosphorylation of STAT3, JAK2 and Src. SD-1008 also reduces STAT3-dependent luciferase activity. SD-1008 enhances apoptosis induced by Paclitaxel in ovarian cancer cells via directly blocking the JAK-STAT3 signaling pathway <sup>[1]</sup> .	
IC <sub>50</sub> & Target	JAK2	STAT3

## **REFERENCES**

[1]. Duan Z, et al. 8-benzyl-4-oxo-8-azabicyclo[3.2.1]oct-2-ene-6,7-dicarboxylic acid (SD-1008), a novel janus kinase 2 inhibitor, increases chemotherapy sensitivity in human ovarian cancer cells. Mol Pharmacol. 2007;72(5):1137-1145.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Inhibitors

Proteins